

# Supporting Information

## Responsive manganese-based nanoplatform amplifying cGAS-STING activation for immunotherapy

*Qingbin He,<sup>1,2</sup> Runxiao Zheng<sup>2</sup>, Junchi Ma<sup>1</sup>, Luyang Zhao<sup>2</sup>, Yafang Shi<sup>2</sup>,*

*Jianfeng Qiu<sup>3\*</sup>*

1. School of Radiology, Shandong First Medical University & Shandong Academy of  
Medical Sciences, Tai'an, 271000, China


2. Medical Science and Technology Innovation Center, Shandong First Medical  
University & Shandong Academy of Medical Sciences, Jinan 250000, China

3. School of Radiology, the Second Affiliated Hospital of Shandong First Medical  
University, Tai'an, 271016, China

*Corresponding author:*

*Jianfeng Qiu*

*The Second Affiliated Hospital of Shandong First Medical University, School of  
Radiology, Shandong First Medical University & Shandong Academy of Medical  
Sciences, No. 619 Changcheng Road, Tai'an, 271016, China, jfqiu100@163.com*




19

20 **Figure S1.** High performance liquid chromatography (HPLC) calibration curve for  
21 measuring ZPP loading efficiency. According to the standard curve of ZPP, the mass  
22 content of ZPP is 90.77 µg/mL in MPCZ solutions (2 mg/mL), equivalented to 4.54  
23 wt%.

24


25



26

27 **Figure S2.** Thermal gravimetric analysis (TGA) of MnO<sub>2</sub>, MP NPs and MPC NPs. The  
 28 mass fractions of PDA and NH<sub>4</sub>HCO<sub>3</sub> in MP and MPC can be estimated by matching  
 29 their mass loss with that of MnO<sub>2</sub>, respectively. According to the standard curve of ZPP,  
 30 the mass content of ZPP is 62.5 μg/mg (ZPP/MnO<sub>2</sub>). The estimated mass fractions of  
 31 MnO<sub>2</sub>, PDA, NH<sub>4</sub>HCO<sub>3</sub>, and ZPP in MPCZ are 71.9%, 21.3%, 2.1%, and 4.7%,  
 32 respectively, based on the measurements mentioned above.

33




34

35 **Figure S3.** DLS characterization (A) hydrodynamic sizes and (B) size distribution of

36 SiO<sub>2</sub>, hMnO<sub>2</sub> and MPCZ NPs in H<sub>2</sub>O.


37



38

39 **Figure S4.** Infrared thermal images of MPCZ (400  $\mu\text{g}/\text{mL}$ ) and  $\text{MnO}_2$  (400  $\mu\text{g}/\text{mL}$ ).

40



41


42 **Figure S5.** The TEM images of MPCZ NPs under NIR laser irradiation ( $1 \text{ W/cm}^2$ , 10

43 min).

44

45

46



47


48 **Figure S6.** TEM images of MPCZ NPs after incubation in PBS solution (pH = 6.5)

49 with 5 mM GSH under NIR laser irradiation (1 W/cm<sup>2</sup>, 10 min).

50

51

52



53

54 **Figure S7.** Percentages of released ZPP from MPCZ NPs over time with presence or  
 55 absence of GSH and NIR laser irradiation according to HPLC.

56

57


58

59

60



61




62

63 **Figure S8.** The release of CXCL10 from PBS, MPC NPs and MPCZ NPs treated 4T1  
64 cells with or without NIR laser irradiation detected by ELISA kit (n=3). Labeled  
65 asterisk represents statistical significance compared with PBS group via one-way  
66 ANOVA with the Tukey post-hoc test. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

67

68




69

70 **Figure S9.** Fluorescence images of main organs and tumors at 24 h post-injection of

71 free Cy5.

72




73

74 **Figure S10.** Blood biochemical analysis of liver function. AST, aspartate transferase;

75 ALT, alanine transferase.

76




77

78 **Figure S11.** Blood biochemical analysis of kidney function. BUN, blood urea nitrogen;

79 CREA, creatinine.

80



81

82 **Figure S12.** Blood hematological analysis of PBS and MPCZ NPs (with or without


83 NIR) 14 days post-injection. RBC, red blood cells; ALB, serum albumin; HGB,

84 hemoglobin; HCT, hematocrit; MCV, mean capsular volume; MCH, mean capsular

85 hemoglobin; MCHC, mean capsular hemoglobin concentration; WBC, white blood

86 cells, PLT, platelets.


87



88

89 **Figure S13.** H&E staining of major organs from different groups without NIR  
 90 irradiation. The mice were intravenously administered PBS, MPC, MPCZ (comparable  
 91 to 20 mg/kg mouse for MPC and 1 mg/kg mouse for ZPP). After 14 days of treatment,  
 92 the major organs (heart, liver, spleen, lung and kidney) of different groups of mice were  
 93 obtained for H&E staining.

94



95

96 **Figure S14.** H&E staining of major organs from different groups with NIR laser

97 irradiation. The mice were intravenously administered PBS, MPC, MPCZ (comparable


98 to 20 mg/kg mouse for MPC and 1 mg/kg mouse for ZPP). After 24 h, the tumor region

99 was irradiated under NIR laser irradiation of 1 W/cm<sup>2</sup> for 10 min. After 14 days of

100 treatment, the major organs (heart, liver, spleen, lung and kidney) of different groups

101 of mice were obtained for H&E staining.

102




103

104 **Figure S15.** Representative photographs of mice at the beginning of treatment.

105

106






107

108 **Figure S16.** Tumor growth curves of mice for the abscopal tumors assay (n = 5, mean  
 109 ± SD).

110




111

112 **Figure S17.** Tumor tissue staining by TUNEL after 14 days of treatments.

113

114



115


116 **Figure S18.** Flow cytometric analysis for evaluating CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes

117 in spleen.

118

119

120



121

122 **Figure S19.** Fluorescence staining of CD4<sup>+</sup> or CD8<sup>+</sup> T lymphocytes in tumor tissues

123 after 14 days of treatments.

124

125

126